Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Localized Estrogen Receptor-Positive Breast Carcinoma”

9 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 9 of 9 results

Large-scale testing (Phase 3)Study completedNCT00256698
What this trial is testing

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

Who this might be right for
Breast Cancer
AstraZeneca 514
Testing effectiveness (Phase 2)Looking for participantsNCT07191717
What this trial is testing

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

Who this might be right for
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+3 more
Jonsson Comprehensive Cancer Center 42
Testing effectiveness (Phase 2)Looking for participantsNCT06964906
What this trial is testing

Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer

Who this might be right for
ER+/HER2- Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine 30
Early research (Phase 1)Ended earlyNCT04185311
What this trial is testing

Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Who this might be right for
Anatomic Stage 0 Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage IA Breast Cancer AJCC v8+19 more
Jonsson Comprehensive Cancer Center 6
Testing effectiveness (Phase 2)Study completedNCT03106077
What this trial is testing

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIB Breast Cancer AJCC v8+18 more
M.D. Anderson Cancer Center 96
Very early researchLooking for participantsNCT05659797
What this trial is testing

FES BPET-DBT in Newly Diagnosed Breast Cancer

Who this might be right for
Breast Cancer
Abramson Cancer Center at Penn Medicine 20
Testing effectiveness (Phase 2)Study completedNCT05549505
What this trial is testing

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Who this might be right for
Breast Cancer
Arvinas Inc. 152
Early research (Phase 1)Active Not RecruitingNCT04052555
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast Cancer

Who this might be right for
Bilateral Breast CarcinomaHER2-Negative Breast CarcinomaLocalized Breast Carcinoma+2 more
National Cancer Institute (NCI) 42
Testing effectiveness (Phase 2)Study completedNCT00407888
What this trial is testing

Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery

Who this might be right for
Estrogen Receptor-positive Breast CancerHER2-positive Breast CancerStage IA Breast Cancer+6 more
University of Washington 60